Disease · EFO_0020925

angina unstable

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. angina unstable. Diseases, record EFO_0020925. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0020925

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: angina unstable
Open Targets ID: EFO_0020925
Highest stage of its drugs: Approval, for 9 of its 44 drugs, from EMA Human Drugs and PMDA

Source Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PRASUGREL	CHEMBL1201772	Small molecule	Approval	EMA Human Drugs	6	4	4	Drugs and targets
TICAGRELOR	CHEMBL398435	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	PMDA	3	0	0	Drugs and targets
FONDAPARINUX SODIUM	CHEMBL1200644	Oligosaccharide	Approval	EMA Human Drugs	2	0	0	Drugs and targets
CLOPIDOGREL BISULFATE	CHEMBL1083385	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
EPTIFIBATIDE	CHEMBL1174	Protein	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
LANSOPRAZOLE	CHEMBL480	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
PRASUGREL HYDROCHLORIDE	CHEMBL1201773	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
VONOPRAZAN FUMARATE	CHEMBL2064032	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets83

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	6	Antithrombin-III activator	Approval	https://conductscience.org/library/genes/462	Drugs and targets
ADRB1	Adrenergic receptor beta	5	Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
P2RY12	P2Y purinoceptor 12	5	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator	Approval	https://conductscience.org/library/genes/64805	Drugs and targets
ADRB2	Adrenergic receptor beta	2	Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
ATP4A	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
F2	Prothrombin	2	Thrombin inhibitor	Phase 3	https://conductscience.org/library/genes/2147	Drugs and targets
ITGA2B	Integrin alpha-IIb/beta-3	2	Integrin alpha-IIb/beta-3 inhibitor	Approval	https://conductscience.org/library/genes/3674	Drugs and targets
ITGB3	Integrin alpha-IIb/beta-3	2	Integrin alpha-IIb/beta-3 inhibitor; Integrin alpha-V/beta-3 inhibitor	Approval	https://conductscience.org/library/genes/3690	Drugs and targets
SCNN1A	Amiloride-sensitive sodium channel, ENaC	2	Amiloride-sensitive sodium channel, ENaC blocker	Phase 2/3	https://conductscience.org/library/genes/6337	Drugs and targets

1 to 10 of 83

See all 83 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00699998	A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects	Phase 3	9,326	2013-05-07	Acute Coronary Syndrome	CLOPIDOGREL, PRASUGREL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00508924	Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)	Phase 2	140	2012-12-05	Coronary Artery Disease, Angina, Unstable	ARGATROBAN, HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT00116857	Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors	Phase 3	122	2012-09-12	Cardiovascular Diseases, Depression, Heart Diseases, Myocardial Infarction, Angina, Unstable	OMEGA-3 FATTY ACIDS, SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT01107899	Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes	Phase 1	29	2012-01-12	Acute Coronary Syndromes	CLOPIDOGREL, PRASUGREL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00139815	Michelangelo - Oasis 5	Phase 3	20,078		Thromboembolism	ENOXAPARIN, FONDAPARINUX	Open Targets' reading of its record	ClinicalTrials.gov
NCT01076764	Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy	Phase 3	13,220		Acute Coronary Syndrome	OTAMIXABAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01787110	An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction	Phase 3	6,629		Acute Coronary Syndrome, Non-ST Elevation (NSTEMI) Myocardial Infarction, Acute ST Segment Elevation Myocardial Infarction, Angina, Unstable	OXYGEN	Its record names the disease	ClinicalTrials.gov
NCT00269906	A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty	Phase 3	1,265		Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary	ABCIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01779401	Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients	Not applicable	1,078		Coronary Heart Disease	CILOSTAZOL, CLOPIDOGREL	Open Targets' reading of its record	ClinicalTrials.gov
NCT05878535	METFORMIN FOR ATRIAL FIBRILLATION	Phase 2	770		Atrial Fibrillation	METFORMIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Prasugrel vs Clopidogrel: serious adverse events	1,573 of 4,623	1,594 of 4,617	9,240	NCT00699998	Trial comparisons
Sertraline Plus Omega-3 Supplement vs Sertraline/Corn Oil: serious adverse events	0 of 62	0 of 60	122	NCT00116857	Trial comparisons

Papers from its trials53

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31529295	RESULT	1	PubMed
26176325	RESULT	1	PubMed
23995608	RESULT	1	PubMed
20226548	RESULT	1	PubMed
19843899	RESULT	1	PubMed
16537663	RESULT	1	PubMed
15514282	RESULT	1	PubMed
9164316	RESULT	1	PubMed
36017088	DERIVED	1	PubMed
35224730	DERIVED	1	PubMed

1 to 10 of 53

See all 53 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0020925

GET https://conductscience.org/api/diseases/v1/EFO_0020925/drugs?page=2

API reference For AI assistants